Text For Citation: 01 Item/Group: 009A Hazard:

29 CFR 1926.62(j)(1)(i): The employer did not make available initial medical surveillance, consisting of biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels, to employees occupationally exposed on any day to lead at or above the action level: a) On July 6, 2017, the employer did not make initial medical surveillance in the form of blood sampling and analysis for lead and zinc protoporphyrin upon employees initial exposure to lead at or above the action level. Employee(s) engaged in lead abatement tasks, using manual scraping or sandblasting methods received their initial monitoring weeks or months after their first assignment to the Old Main Post Office. (1) An employee assigned to the worksite on October 4, 2016, was not provided biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels until July 20, 2017, approximately 9 months after initial assignment. (2) An employee assigned to the worksite on October 12, 2016, was not provided biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels until June 22, 2017, approximately 8 months after initial assignment. (3) An employee assigned to the worksite on October 12, 2016, was not provided biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels until June 23, 2017, approximately 8 months after initial assignment. (4) An employee assigned to the worksite on January 3, 2017, was not provided biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels until June 22, 2017, approximately 5 months after initial assignment. (5) An employee assigned to the worksite on January 18, 2017, was not provided biological monitoring in the form of blood sampling and analysis for lead and zinc protoporphyrin levels until June 30, 2017, approximately 5 months after initial assignment.